Cell adhesion and extracellular matrix protein-protein interfaces (CAM-ECM PPIs)

This target entry represents a broad category of protein-protein interfaces (PPIs) involving heparin-binding adhesion molecules, integrins, fibronectin, and selectins, rather than a single molecular entity. These interfaces are critical for mediating cell-cell and cell-extracellular matrix (ECM) interactions, which govern essential biological processes such as leukocyte trafficking, platelet aggregation, and tissue scaffolding. Integrins act as transmembrane linkers between the ECM (e.g., fibronectin) and the intracellular cytoskeleton, while selectins facilitate the initial rolling of white blood cells on vascular endothelium. Heparin-binding domains within these proteins often regulate their affinity and spatial organization by interacting with cell-surface proteoglycans. In disease states, these interfaces are frequently co-opted to facilitate cancer metastasis, chronic inflammation, and pathological thrombosis. Therapeutic strategies targeting these PPIs include monoclonal antibodies and small molecules designed to block ligand binding, thereby inhibiting downstream signaling and cellular recruitment. Due to the diversity of molecules included in this description, it is classified as a multi-target interface group rather than a single therapeutic target.

Other names

Heparin-binding adhesion moleculesIntegrin-ligand interfacesFibronectin-integrin complexSelectin-ligand interfacesCell-matrix adhesion interfaces

Inhibition of protein-protein interactions between cell surface receptors (integrins, selectins) and their ligands (fibronectin, VCAM-1, MAdCAM-1, P-selectin glycoprotein ligand-1) to prevent cell adhesion and signaling.